This announcement is a separate document:
自愿披露口服PROTAC药物HP518片拟用于治疗雄激素受体（AR）阳性三阴乳腺癌获美国FDA授予快速通道认定的公告
Announcement on voluntary disclosure of oral PROTAC drug HP518 intended for the treatment of androgen receptor (AR) positive triple-negative breast cancer granted Fast Track designation by the US FDA.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.